DPP4 and type 2 diabetes mellitus: Several treatments for type 2 diabetes (e.g. sulfonylureas, meglitinides, glucagon-like peptide-1 [GLP-1] receptor agonists and dipeptidyl peptidase-4 [DPP-4] inhibitors) directly stimulate beta cells to increase insulin release.